https://www.selleckchem.com/products/gsk621.html
PURPOSE Previous SEER (Surveillance, Epidemiology, and End Results)-Medicare analyses have shown no definitive survival benefit for adjuvant chemotherapy (AC) with fluoropyrimidines. Impact of oxaliplatin-containing regimens for elderly stage II patients in real-world setting is unknown. We explored the utilization and outcome of AC after the Food and Drug Administration (FDA) approval of oxaliplatin. PATIENTS AND METHODS Patients with stage II colon cancer (2004-2011) who underwent resection were selected for this analysis. Medicare cla
Like
Comment
Share
